The effect of Friso Premature on growth, sleep characteristics, Nutritional status parameters and inflammatory markers.

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON25053

Source

Health condition

Sleep efficiency, growth, nutritional status, inflammatory markers.

Slaap efficientie, groei, voedingskundige status, ontstekings indicatoren.

Sponsors and support

Primary sponsor: Specialized Hospital for Active Treatment of Children's Disease, Sofia, Bulgaria **Source(s) of monetary or material Support:** FrieslandCampina

Intervention

Outcome measures

Primary outcome

- 1. Growth;
- 2. Sleep efficiency;
 - 1 The effect of Friso Premature on growth, sleep characteristics, Nutritional stat ... 5-05-2025

3. Nutritional status of iron, vitamin D, vitamin A, folic acid, and DHA-AA.

Secondary outcome

Inflammatory markers in blood and urine.

Study description

Background summary

In 2010 the ESPGHAN released new recommendations with regard to the composition of formulae for preterm infants. This resulted in quite some discussions about the necessity of some changes. For that reasons it was decided to look for the differences in outcome between the current and ESPGHAN aligned composition. Furthermore, the use of protein hydrolysate should show off in a more tolerable product for preterm infants.

Study objective

The addition of a whey protein hydrolysate will improve sleep onset and efficiency and will not limit growth in weight, length and head circumference as compared to the control preterm formula at the age of 10 weeks.

Because of the alkaline composition, nocturnal acidosis will be significantly lower as compared with the current available preterm formula during the course of the study.

Nutritional status of iron, vitamin A, vitamin D, DHA-AA and folic acid will be more close to normal/required as compared to the current formula at the age of 10 weeks.

Inflammatory and oxidation markers will be lower than in case of the current preterm formula during the course of the study.

Study design

The intervention period will last for 8 weeks and the several parameters will be studied at the start (age 14±2 days), and at the age of 30 ± 2 days, 45 ± 2 days and 75 ± 2 days. Venous blood samples will only be collected at 14 ± 2 days and 75 ± 2 days.

Methods of measurement:

1. Anthropometry: Body weight, height and head circumference according to standard procedures;

2 - The effect of Friso Premature on growth, sleep characteristics, Nutritional stat ... 5-05-2025

2. Tolerance: Based on 3-days diary;

3. Sleep onset and efficieny: By 3 days Actiwatch monitoring and sleep diary;

4. Metabolic acidification: pH measurement of early morning urine, as well as the analysis of potassium and creatinin in urine;

5. Nutritional status parameters: Vitamin D [25(OH)D], vitamin A [serum retinol & retinol binding protein], iron [Hb, serum ferritin, soluble transferrin receptors], folic acid [serum folate] and total homocysteine according to the standard procedures of the Free University medical center, Amsterdam, The Netherlands. Red blood cell fatty acid composition according to the standard procedure of the University Medical Center Groningen, The Netherlands;

6. Inflammatory status: F2 isoprostanes in early morning urine and c-reactive protein, Interleukin-6 and TNF-alpha in plasma, according to standard procedures of the Free University medical center, Amsterdam, The Netherlands.

Intervention

A. Current formulae for preterm infants during the hospital phase (till 3500 g of body weight);

B. Preterm formulae with protein hydrolysate, and increased levels of some vitamins and minerals in accordance with the ESPGHAN guidelines.

Contacts

Public P.O.Box 226 Anne Schaafsma Leeuwarden 8901 MA The Netherlands +31 (0)58 2992424 Scientific P.O.Box 226 Anne Schaafsma Leeuwarden 8901 MA The Netherlands +31 (0)58 2992424

Eligibility criteria

Inclusion criteria

- 1. Apparently healthy infants, appropriate for gestational age (AGA);
- 2. Gestational age of 32 up to but not including 35 (ongoing) weeks;
- 3. Full enteral nutrition;
- 4. Not younger than 2 or older than 3 weeks of age at inclusion;
- 5. Bottle fed;
- 6. Being able and willing to drink milk;
- 7. No medical recognized mental problems.

Exclusion criteria

1. Human milk consumption;

2. Congenital malformations or conditions known to affect growth (e.g. severe broncho pulmonary dysplasia, inborn error of metabolism, cardiac or renal disease, necrotizing enterocolitis with substantial gut loss, and grade IV intraventricular hemorrhage);

3. Lactose intolerance;

4. Familiar history of impaired iron metabolism (haptoglobin Hp2-2, hemochromatosis, sickelcell anemia, thalassemia);

- 5. Medications that may effect digestion or absorption of food, or affect sleep;
- 6. Blood transfusions;
- 7. Vitamin supplements during the intervention period.

Study design

Design

Study type: Intervention model: Interventional

Parallel

4 - The effect of Friso Premature on growth, sleep characteristics, Nutritional stat ... 5-05-2025

Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-04-2012
Enrollment:	60
Туре:	Anticipated

Ethics review

Positive opinion	
Date:	29-03-2012
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL3221
NTR-old	NTR3373
Other	FrieslandCampina : Nutr-AS-004-2011
ISRCTN	ISRCTN wordt niet meer aangevraagd.

5 - The effect of Friso Premature on growth, sleep characteristics, Nutritional stat ... 5-05-2025

Study results

Summary results

N/A